Natalia Navas

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 5

Top Topics

Monoclonal Antibody

Top Venues

Analytical methods : advancing methods and applications

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Jesús Hermosilla, Airan Alonso-García, Antonio Salmerón-García, José Cabeza-Barrera, Antonio Luis Medina-Castillo, Raquel Pérez-Robles, Natalia Navas
Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate. Vaccines 11 (11) (2023)
Anabel Torrente-López, Jesús Hermosilla, Antonio Salmerón-García, José Cabeza-Barrera, Natalia Navas
Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress. Pharmaceutics 14 (4) (2022)
Raquel Pérez-Robles, Antonio Salmerón-García, Susana Clemente-Bautista, Inés Jiménez-Lozano, María Josep Cabañas-Poy, Jose Cabeza, Natalia Navas
Method for identification and quantification of intact teduglutide peptide using (RP)UHPLC-UV-(HESI/ORBITRAP)MS. Analytical methods : advancing methods and applications 14 (43) (2022)
Anabel Torrente-López, Jesús Hermosilla, Natalia Navas, Luis Cuadros-Rodríguez, José Cabeza-Barrera, Antonio Salmerón-García
The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. Vaccines 9 (6) (2021)
Jesús Hermosilla, Ricardo Sánchez-Martín, Raquel Pérez-Robles, Antonio Salmerón-García, Salvador Casares, Jose Cabeza, Luis Cuadros-Rodríguez, Natalia Navas
Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA). BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 33 (2) (2019)